+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Microbiome Therapeutics Market 2020: A Benchmark of the Top 10 Companies

  • ID: 5230492
  • Report
  • December 2020
  • Region: Global
  • 34 Pages
  • Frost & Sullivan
A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

FEATURED COMPANIES

  • 4D Pharma PLC
  • ENTEROME
  • Finch Therapeutics
  • Intralytix
  • Locus Biosciences
  • Microbiotica

This report profiles companies actively involved in developing microbiome therapeutics.

Microbiome present in the human body has a major role to play in the overall functioning of the human body. Human microbiota consists of a diverse population of bacterial, viral and eukaryotic communities and is present on skin, nasopharynx, oral cavity, respiratory tract, gastrointestinal tract and female reproductive tract. The naturally occurring microbiota is actively involved in metabolic cycle and the performance of immune system.

Today, with deeper understanding of microbiome and its role in human health, we are able to utilize microbiome for developing therapeutics. Designing microbial therapeutics has been challenging, however with the help of genetic engineering tools manipulating these naturally occurring consortia of microbiome has gained momentum in the last five years.

Numerous studies are being conducted to gain deeper understanding of host-microbiome interaction for developing targeted therapeutics. A significant focus of human microbiome research has been studying the bacteria in the gut, which represent the largest community both in terms of abundance and diversity. Microbiome therapeutics companies are increasingly involved in developing therapies for dysbiosis, obesity, inflammatory bowel disease, cancer, even neurological disorders as schizophrenia and autism.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4D Pharma PLC
  • ENTEROME
  • Finch Therapeutics
  • Intralytix
  • Locus Biosciences
  • Microbiotica

1. Strategic Imperative and Growth Environment

  • Strategic Imperative
  • Growth Environment

2. The Radar: Microbiome Therapeutics

3. Companies to Action

  • 4D Pharma PLC
  • ENTEROME
  • Finch Therapeutics
  • Intralytix
  • Locus Biosciences
  • Microbiotica
  • Second Genome
  • Seres Therapeutics
  • Rebiotix - Ferring Pharmaceuticals
  • Vedanta Biosciences

4. Strategic Insights

5. Next Steps: Leveraging The Radar to Empower Key Stakeholders

  • Significance of Being on The Radar
  • The Radar Empowers the CEO’s Growth Team
  • The Radar Empowers Investors
  • The Radar Empowers Customers
  • The Radar Empowers the Board of Directors

6. The Radar: Analytics

  • The Radar: Benchmarking Future Growth Potential
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 4D Pharma PLC
  • ENTEROME
  • Finch Therapeutics
  • Intralytix
  • Locus Biosciences
  • Microbiotica
  • Rebiotix - Ferring Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Vedanta Biosciences
Note: Product cover images may vary from those shown
Adroll
adroll